Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market. Read More
What Happened? Shares of clinical research company IQVIA (NYSE: IQV) jumped 8.4% in the afternoon session after it reported strong first-quarter 2026 financi...
Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 8.4% year on year to $4.15 billi...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended March 31, 2026.
Clinical research company IQVIA (NYSE: IQV) will be reporting results this Tuesday before the bell. Here’s what you need to know. IQVIA beat analysts’ revenu...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a pioneer in AI-driven clinical research, for a staggering $47.8 billion. The deal represents the largest "Tech-Bio" merger in
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced at NVIDIA GTC the launch of IQVIA.ai, a unified agentic AI platform purpose-built to help life sciences organizations transform how they operate, make decisions and innovate across clinical, commercial and real-world domains.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
On March 5, 2026, Veeva Systems Inc. (NYSE: VEEV) reminded the market why it remains the undisputed heavyweight of life sciences software. Following a blockbuster Q4 fiscal year 2026 earnings report and an optimistic forward guidance, the stock surged 11% in mid-day trading. This rally serves as a definitive "vote of confidence" for a company [...]
As the sun sets on the final quarter of the 2026 fiscal year, Veeva Systems (NYSE: VEEV) has once again proven its mettle in the volatile world of vertical software. Reporting its Q4 results on March 4, 2026, the life sciences cloud leader posted revenue of $810 million, hitting the
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, at 9:30 a.m. ET.
